161 related articles for article (PubMed ID: 36322543)
21. Phylogeny and Classification of Human Papillomavirus (HPV)16 and HPV18 Variants Based on E6 and L1 genes in Tunisian Women with Cervical Lesions.
Jendoubi-Ferchichi M; Satouri L; Ghoul F; Malek-Mellouli M; Derbel AM; Makni MK; Reziga H; Baba A; Zili M; Segondy M; Khelifa R
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3361-3366. PubMed ID: 30583341
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
Lang Kuhs KA; Kreimer AR; Trivedi S; Holzinger D; Pawlita M; Pfeiffer RM; Gibson SP; Schmitt NC; Hildesheim A; Waterboer T; Ferris RL
Cancer; 2017 Nov; 123(22):4382-4390. PubMed ID: 28950407
[TBL] [Abstract][Full Text] [Related]
23. Two-step chromatographic purification of glutathione S-transferase-tagged human papillomavirus type 16 E6 protein and its application for serology.
Xu ML; Kim SC; Kim HJ; Ju W; Kim YH; Kim HJ
Protein Expr Purif; 2017 Apr; 132():19-26. PubMed ID: 28089881
[TBL] [Abstract][Full Text] [Related]
24. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
[TBL] [Abstract][Full Text] [Related]
25. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
26. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
27. Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18.
Trevisan A; Wissing MD; Dagenais C; Forest P; Ramanakumar AV; Burchell AN; Franco EL; Coutlée F; Couillard M
J Gen Virol; 2021 May; 102(5):. PubMed ID: 34043499
[TBL] [Abstract][Full Text] [Related]
28. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
30. Genetic variability and lineage phylogeny of human papillomavirus type-16 and -53 based on the E6, E7, and L1 genes in Southwest China.
Cao M; Chenzhang Y; Ding X; Zhang Y; Jing Y; Chen Z
Gene; 2016 Oct; 592(1):49-59. PubMed ID: 27450917
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.
Anantharaman D; Gheit T; Waterboer T; Abedi-Ardekani B; Carreira C; McKay-Chopin S; Gaborieau V; Marron M; Lagiou P; Ahrens W; Holcátová I; Merletti F; Kjaerheim K; Talamini R; Simonato L; Castellsague X; Macfarlane TV; Biggs AM; Thakker N; Znaor A; Thomson P; Canova C; Conway DI; Healy CM; Tommasino M; Pawlita M; Brennan P
J Natl Cancer Inst; 2013 Apr; 105(8):536-45. PubMed ID: 23503618
[TBL] [Abstract][Full Text] [Related]
32. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
Gene; 2021 May; 782():145533. PubMed ID: 33636291
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of human papillomavirus infection among females and the genetic variations of HPV18 and HPV58 in Henan province, China.
Wang Y; Han S; Wang X; Song S; Wang X
Sci Rep; 2023 Feb; 13(1):2252. PubMed ID: 36755053
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
35. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
36. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
37. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.
Rizk RZ; Christensen ND; Michael KM; Müller M; Sehr P; Waterboer T; Pawlita M
J Gen Virol; 2008 Jan; 89(Pt 1):117-129. PubMed ID: 18089735
[TBL] [Abstract][Full Text] [Related]
38. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.
Scherpenisse M; Schepp RM; Mollers M; Mooij SH; Meijer CJ; Berbers GA; van der Klis FR
Clin Vaccine Immunol; 2013 Aug; 20(8):1329-32. PubMed ID: 23740920
[TBL] [Abstract][Full Text] [Related]
39. Capsomer vaccines protect mice from vaginal challenge with human papillomavirus.
Wu WH; Gersch E; Kwak K; Jagu S; Karanam B; Huh WK; Garcea RL; Roden RB
PLoS One; 2011; 6(11):e27141. PubMed ID: 22069498
[TBL] [Abstract][Full Text] [Related]
40. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
